No, No, No: PBAC justifies three rejections
Australians are waiting longer for subsidised access to effective medicines addressing an unmet need due to concerns over long-term treatment effects and difficulties in ascertaining treatment populations, suggesting more flexible pathways need to added to the HTA process.
To see the whole article, log in or create an account.